FIELD: biotechnology.
SUBSTANCE: method for identifying a candidate peptide presented by the major histocompatibility complex (MHC) is described. The method includes the following steps: expressing a recombinant MHC-peptide complex in a reporter cell line; detecting and isolating cells that express one or more recombinant(s) complex(s) MHC-peptide on the cell surface; determining the amino acid sequence of the candidate peptide that is presented on the cell surface of the cell isolated in the previous step; identifying the candidate peptide as presented by MHC. Also a method for determining the binding affinity of MHC to a candidate peptide is described.
EFFECT: technical result is providing means and methods for reliable identification of peptides, in particular TSAs, which are effectively presented by APCs.
39 cl, 9 dwg, 4 ex
Title |
Year |
Author |
Number |
METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE |
2019 |
- Aftab, Blake, T.
- Pham, Christina
- Shen, Rhine
- Wu, Michelle
|
RU2800920C2 |
EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM |
2009 |
- Nisimura,Jasukharu
- Imai,Katsunori
- Nakamura,Jusuke
- Tsunoda,Takuja
|
RU2532105C2 |
GENETICALLY MODIFIED MHISTOCOMPATIBILITY COMPLEX MICE |
2012 |
- Makdonald Linn
- Merfi Endryu Dzh.
- Gurer Kagan
- Makvirter Dzhon
- Voronina Vera
- Kharris Fejt
- Stivens Shon
|
RU2783984C2 |
URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME |
2015 |
- Tsunoda, Takuya
- Osawa, Ryuji
- Yamashita, Sachiko
- Watanabe, Tomohisa
- Hikichi, Tetsuro
|
RU2700881C2 |
GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX |
2012 |
- Makdonald Linn
- Merfi Endryu Dzhej
- Tu Naksin
- Gurer Tsagan
- Voronina Vera
- Stivens Shon
|
RU2797549C2 |
MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS |
2011 |
|
RU2603075C2 |
PHARMACEUTICAL, CONTAINING EPITOPE PEPTIDES HIG2 AND URLC10, FOR CANCER TREATMENT, METHODS AND MEANS FOR INDUCTION OF ANTIGEN-PRESENTING CELL AND CYTOTOXIC T-LYMPHOCYTE (CTL), ANTIGEN-PRESENTING CELL AND CTL, OBTAINED THEREOF, METHOD AND MEANS OF IMMUNE ANTI-CANCER RESPONSE |
2009 |
- Tsunoda Takuja
- Okhsava Rjudzi
- Josimura Satiko
|
RU2529373C2 |
METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY |
2018 |
|
RU2799341C2 |
INDIVIDUALIZED ANTI-TUMOR VACCINES |
2012 |
- Sakhin Ugur
- Krajter Sebastyan
- Diken Mustafa
- Dikmann Yan
- Kozlovski Mikhael
- Britten Tsedrik
- Kestl Dzhon
- Lever Martin
- Renard Bernkhard
- Omokoko Tana
- De Graf Jokhannes Khendrikus
|
RU2779946C2 |
STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE |
2016 |
- Long, Li
- Xiang, Jingyi
- Xu, Yiyang
- Liu, Hong
- Liu, Cheng
|
RU2754041C2 |